Supernus Pharma (NASDAQ: SUPN) reported Q2 GAAP EPS of $0.14, which may not compare to the analyst estimate of $0.37. Revenue for the quarter came in at $170.1 million versus the consensus estimate of $165.94 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.